Immupharma (LSE:IMM)
Historical Stock Chart

From Apr 2019 to Apr 2024

TIDMIMM

RNS Number : 4650O

Immupharma PLC

18 August 2017

18 August 2017

ImmuPharma Plc

AIM Rule 17 Notice

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces pursuant to Rule 17 of the AIM Rules for Companies ("AIM Rules"), the following director's disclosure under Schedule Two, Paragraph (g) of the AIM Rules:

Tim McCarthy, the Company's Non-executive Chairman, previously held roles on the boards of Alizyme Plc and its subsidiary Alizyme Therapeutics Ltd, both of which entered into a Creditors Voluntary Winding-up in December 2009, within 12 months of his resignation.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Ends

 
 For further information please contact: 
                                           + 44 (0) 20 
   ImmuPharma plc (www.immupharma.org)       7152 4080 
   Tim McCarthy, Chairman 
   Lisa Baderoon, Head of Investor 
    Relations                             + 44 (0) 7721 
    Twitter: @immupharma                      413496 
   Northland Capital Partners Limited 
    (NOMAD & Broker) 
    Patrick Claridge, David Hignell, 
    Jamie Spotswood, Corporate Finance    +44 (0)20 3861 
    Rob Rees, Corporate Broking                6625 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCOKFDKABKDOFD

(END) Dow Jones Newswires

August 18, 2017 12:09 ET (16:09 GMT)